ArticleExperimental and therapeutic medicine2026
Comparative study on mouse models of acute exacerbation of pulmonary fibrosis.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiology and underlying mechanisms of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) remain poorly understood. Although several animal models have been developed to study AE-IPF, a systematic evaluation and comparison of these models has not yet been reported. In the present study, PF was induced in mice by a single intratracheal administration of bleomycin (BLM). On day 14 after the initial BLM challenge, AE-PF in mice was induced by intratracheal re-challenge with replication-deficient adenoviral vectors (ADV), lipopolysaccharide (LPS) or a second dose of BLM. Micro-chest computed tomography (CT) was performed on day 20, and blood, bronchoalveolar lavage fluid (BALF) and lung tissue samples were collected after sacrifice on day 21. Compared with mice receiving a single dose of BLM alone, all three AE-PF groups exhibited significant body weight loss and increased mortality (with the highest mortality in the LPS group), as well as more extensive lung injury on CT. Histopathological scores for inflammation and fibrosis, hydroxyproline content and expression levels of fibrotic markers (fibronectin, collagen I, α-smooth muscle actin and MMP7) were significantly elevated in the AE-PF groups. Inflammatory cytokines (IL-6, IL-1β and TNF-α) were markedly increased in both serum and BALF. Furthermore, the AE-PF models showed downregulation of alveolar epithelial cell markers (E-cadherin and pro-surfactant protein C) and a significant increase in apoptotic activity. Notably, fibrosis progression was more severe in the ADV and two-dose BLM groups than in the LPS group. Taken together, these findings indicate that all three triggers can induce AE-PF through enhanced apoptosis, inflammation and fibrosis. These results support the use of day 14 re-challenge as a standardized model for AE-PF. Among the three models, the ADV-induced AE-PF model may serve as a particularly suitable platform for investigating the pathogenesis of acute exacerbations in idiopathic pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.